-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, due to the accelerated pace of people's life and the deterioration of the living environment, the incidence of skin diseases in China is gradually increasing
.
As the incidence of skin diseases in China has been increasing year by year, the market size of skin disease drugs is also increasing
.
According to data, the scale of China's dermatological drugs market has continued to expand.
In 2020, the market size of dermatological drugs in OTC drugs has reached approximately 18.
87 billion yuan, an increase of 5% over 2019
.
At present, under the widespread demand of the market, pharmaceutical companies are becoming more and more interested in R&D, and more and more companies are also accelerating their entry into this field
.
For example, on September 28, Innovent announced that it will cooperate with unio therapeutic to discuss unio’s main drug candidate orismilast for the treatment of inflammatory skin diseases, a PDE4 inhibitor in clinical phase II, which has reached an agreement in China (including mainland China).
, Hong Kong, Macau and Taiwan)
.
According to the terms of the agreement, Cinda Bio will obtain the exclusive rights to research, development and commercialization of orismilast in China
.
And unio will receive an advance payment of 20 million U.
S.
dollars and is entitled to a milestone payment of no more than 247 million U.
S.
dollars, as well as royalties for the net annual sales of orismilast in China
.
For this cooperation, Cinda Biotech stated that it will add a potential best drug candidate in the mid-stage of clinical development to its existing R&D pipeline
.
Based on the huge unmet needs and solid clinical data, the company hopes that this PDE4 inhibitor will benefit Chinese patients as soon as possible
.
In addition to Cinda Bio, on July 8th, Shandong Dyne Marine Biopharmaceutical and Shandong Liangfu Pharmaceutical also submitted applications for the 4 types of generic tacrolimus ointment and were contracted
.
It is reported that tacrolimus ointment is a best-selling dermatological drug.
In 2020, the total sales in China's public medical institutions and physical pharmacies in cities in China will exceed 400 million yuan
.
The analysis believes that from the current increase in dermatological patients in my country, the market scale of dermatological drugs will continue to maintain a steady growth.
.
With the accelerated deployment of pharmaceutical companies and the implementation of the new medical reform policy, more prescription drugs will enter the retail terminal, making the retail market more competitive, leading to further expansion of China's dermatological drug retail market
.
In this context, the industry suggests that the following development trends of pharmaceutical companies can be focused on
.
It is understood that in the dermatological drug retail market, Xi'an Janssen Pharmaceuticals, Dianhong Pharmaceuticals, and China Resources Sanjiu Pharmaceuticals have been more eye-catching in recent years
.
Among them, Xi'an Janssen Pharmaceuticals has a strong position in the dermatological drug retail market
.
Its main focus is on antifungal drugs, and its long-term advertising investment and brand strategy have made its position in the retail market very strong.
At the same time, brands such as Jindaknin, Dacnin, and Pervisone have become widely known and recognized over-the-counter drugs by the public
.
The core business of China Resources Sanjiu Pharmaceutical is OTC and prescription drugs of traditional Chinese medicine, and its core OTC products also occupy a relatively high market share in the dermatological drug market
.
It is reported that its 999 Piyanping (compound dexamethasone acetate cream, mometasone furoate gel) has a high reputation in the domestic drug market
.
In the first half of 2016, the market shares of compound dexamethasone acetate cream and mometasone furoate gel were 2.
5% and 2.
1% respectively.
In general, under the broad market demand, pharmaceutical companies are interested in research and development.
Getting stronger
.
In the future, with the continuous approval of innovative drugs, the industry predicts that in the field of skin disease treatment, best-selling drugs like AbbVie and Humira may appear
.
.
As the incidence of skin diseases in China has been increasing year by year, the market size of skin disease drugs is also increasing
.
According to data, the scale of China's dermatological drugs market has continued to expand.
In 2020, the market size of dermatological drugs in OTC drugs has reached approximately 18.
87 billion yuan, an increase of 5% over 2019
.
At present, under the widespread demand of the market, pharmaceutical companies are becoming more and more interested in R&D, and more and more companies are also accelerating their entry into this field
.
For example, on September 28, Innovent announced that it will cooperate with unio therapeutic to discuss unio’s main drug candidate orismilast for the treatment of inflammatory skin diseases, a PDE4 inhibitor in clinical phase II, which has reached an agreement in China (including mainland China).
, Hong Kong, Macau and Taiwan)
.
According to the terms of the agreement, Cinda Bio will obtain the exclusive rights to research, development and commercialization of orismilast in China
.
And unio will receive an advance payment of 20 million U.
S.
dollars and is entitled to a milestone payment of no more than 247 million U.
S.
dollars, as well as royalties for the net annual sales of orismilast in China
.
For this cooperation, Cinda Biotech stated that it will add a potential best drug candidate in the mid-stage of clinical development to its existing R&D pipeline
.
Based on the huge unmet needs and solid clinical data, the company hopes that this PDE4 inhibitor will benefit Chinese patients as soon as possible
.
In addition to Cinda Bio, on July 8th, Shandong Dyne Marine Biopharmaceutical and Shandong Liangfu Pharmaceutical also submitted applications for the 4 types of generic tacrolimus ointment and were contracted
.
It is reported that tacrolimus ointment is a best-selling dermatological drug.
In 2020, the total sales in China's public medical institutions and physical pharmacies in cities in China will exceed 400 million yuan
.
The analysis believes that from the current increase in dermatological patients in my country, the market scale of dermatological drugs will continue to maintain a steady growth.
.
With the accelerated deployment of pharmaceutical companies and the implementation of the new medical reform policy, more prescription drugs will enter the retail terminal, making the retail market more competitive, leading to further expansion of China's dermatological drug retail market
.
In this context, the industry suggests that the following development trends of pharmaceutical companies can be focused on
.
It is understood that in the dermatological drug retail market, Xi'an Janssen Pharmaceuticals, Dianhong Pharmaceuticals, and China Resources Sanjiu Pharmaceuticals have been more eye-catching in recent years
.
Among them, Xi'an Janssen Pharmaceuticals has a strong position in the dermatological drug retail market
.
Its main focus is on antifungal drugs, and its long-term advertising investment and brand strategy have made its position in the retail market very strong.
At the same time, brands such as Jindaknin, Dacnin, and Pervisone have become widely known and recognized over-the-counter drugs by the public
.
The core business of China Resources Sanjiu Pharmaceutical is OTC and prescription drugs of traditional Chinese medicine, and its core OTC products also occupy a relatively high market share in the dermatological drug market
.
It is reported that its 999 Piyanping (compound dexamethasone acetate cream, mometasone furoate gel) has a high reputation in the domestic drug market
.
In the first half of 2016, the market shares of compound dexamethasone acetate cream and mometasone furoate gel were 2.
5% and 2.
1% respectively.
In general, under the broad market demand, pharmaceutical companies are interested in research and development.
Getting stronger
.
In the future, with the continuous approval of innovative drugs, the industry predicts that in the field of skin disease treatment, best-selling drugs like AbbVie and Humira may appear
.
